



(51) International Patent Classification:

C07K 14/47 (2006.01) A61P 11/00 (2006.01)
A61K 38/43 (2006.01) A61P 29/00 (2006.01)

(21) International Application Number:

PCT/US2023/067064

(22) International Filing Date:

16 May 2023 (16.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/342,264 16 May 2022 (16.05.2022) US
63/492,692 28 March 2023 (28.03.2023) US

(71) Applicant: INHIBRX, INC. [US/US]; 11025 North Torrey Pines Road, Suite 200, La Jolla, California 92037 (US).

(72) Inventors: KALABUS, James; c/o InhibRx, Inc., 11025 North Torrey Pines Road, Suite 200, La Jolla, California 92037 (US). BHAGWAT, Sharvari; c/o InhibRx, Inc., 11025 North Torrey Pines Road, Suite 200, La Jolla, California 92037 (US).


(74) Agent: KOZAKIEWICZ, Cynthia A. et al.; Cooley LLP, 1299 Pennsylvania Ave. NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: EFFECTIVE DOSAGE OF RECOMBINANT SERPIN-FC FUSION PROTEIN FOR USE IN A METHOD OF TREATING AAT DEFICIENCY IN A SUBJECT

FIG. 1



(57) Abstract: The present application relates to an effective dosage of an aqueous solution comprising an engineered AAT-Fc fusion dimeric protein for use in a method of treating or alleviating a symptom associated with aberrant serine protease activity in a subject in need thereof.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*